The Impact of Conversion From Mycophenolate Mofetil to Mycophenolate Sodium Among Renal Transplant Recipients on a Sirolimus-Based Regimen

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1429-1434

  Kahan, B D ^a   Podbielski, J ^a   Childs, B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ADULT; APPEARANCE CHANGE; ARTICLE; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; DIARRHEA; DRUG EFFECT; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ERUCTATION; FEELING UNWELL; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL QUALITY OF LIFE INDEX; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL SYMPTOM RATING SCALE; GENERAL ASPECTS OF DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT;

ADULT; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; QUALITY OF LIFE; QUESTIONNAIRES; SIROLIMUS; TABLETS, ENTERIC-COATED;

EID: 45449093784     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.04.009     Document Type: Article

References (20)

1. Behrend M. Adverse gastrointestinal effects of mycophenolic mofetil: aetiology, incidence and management. Drug Saf 24 (2001) 645
2. European Mycophenolate Mofetil Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345 (1995) 1321
3. Hardinger L.K., Brennan D.C., Mutinga N., et al. Graft survival and cost following gastrointestinal complications in renal transplant recipients treated with mycophenolate mofetil. Am J Transplant 3 suppl 5 (2003) 56
4. Tierce J.C., Porterfield-Baxa J., Petrilla A.A., et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 19 (2005) 779
5. Bunnapradist S., Lentine K.L., Burroughs T.E., et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82 (2006) 102
6. Budde K., Curtis J., Knoll G., et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
7. Budde K., Knoll G., Curtis J., et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (ECMPS, myfortic). Clin Nephrol 66 (2006) 103
8. Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 36 suppl 2S (2004) 517S
9. Guyatt G.H., Osoba D., Wu A.W., et al. Clinical Significance Consensus Meeting Group: methods to explain the clinical significance of health status measures. Mayo Clin Proc 77 (2002) 371
10. Bolin P., Tanriover B., Zibari G.B., et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 84 (2007) 1443
11. Cofan F., Rosich E., Arias M., et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 39 (2007) 2179
12. Calvo N., Sanchez-Fructuoso A.I., Conesa J., et al. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 38 (2006) 2396
13. Kleinman L., Faull R., Walker R., et al. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications. Transplant Proc 37 (2005) 846
14. Eypasch E., Williams J.I., Wood-Dauphinee S., et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 82 (1995) 216
15. Dimenas E., Glise H., Hallerback B., et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 30 (1995) 1046
16. Abbud-Filho M., Girón F., Hernández E., et al. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc 36 (2004) 1647
17. Pelletier R.P., Soule J., Henry M.L., et al. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol. Clin Transplant 21 (2007) 532
18. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2003) 231
19. Kamar N., Oufroukhi L., Faure P., et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 20 (2005) 2231
20. Pietruck F., Abbud-Filho M., Vathsala A., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc 39 (2007) 103